StockMarketWire.com - AstraZeneca said a trial of a treatment for heart problems showed a reduction in major adverse cardiovascular events.

The company's heart drug Themis taken together with Aspirin had shown a 'statistically-significant reduction in a composite of major adverse cardiovascular event compared to aspirin alone,' the company said.

The trial was conducted in more than 19,000 patients with coronary artery disease and type-2 diabetes with no prior heart attack or stroke, AstraZeneca said.

'Approaches to help reduce cardiovascular morbidity further in patients with coronary artery disease and type-2 diabetes are urgently needed.

The positive result from the THEMIS trial may offer a potential benefit for this high-risk patient population,' said Elisabeth Bjork, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals.

At 4:16pm: [LON:AZN] AstraZeneca PLC share price was +131.5p at 6290.5p



Story provided by StockMarketWire.com